A. Francis

发表

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.

S. Pinder, H. Earl, D. Rea, 2016, Journal of the National Cancer Institute.

Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ.

G. Ball, S. Pinder, E. Sawyer, 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population- Based Cohort Study

L. Fallowfield, J. Iqbal, L. Solin, 2016 .

Abstract OT2-3-01: The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ

S. Pinder, M. Wallis, L. Fallowfield, 2013 .

Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013.

D. Rea, A. Francis, R. Feltbower, 2016, Cancer Epidemiology.

The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project.

S. Pinder, E. Sawyer, A. Evans, 2016, Breast.

Effects of Standard Treatments for Ductal Carcinoma In Situ-Making Informed Choices.

L. Fallowfield, A. Thompson, A. Francis, 2016, JAMA oncology.

HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice

S. Pinder, J. Bartlett, A. Thompson, 2013, Journal of Clinical Pathology.

The LORIS Trial: Addressing overtreatment of ductal carcinoma in situ.

D. Rea, L. Fallowfield, A. Francis, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

Opportunities and priorities for breast surgical research.

M. Reed, J. Harvey, J. Vaidya, 2018, The Lancet. Oncology.

Macroscopic handling and reporting of breast cancer specimens pre‐ and post‐neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches

S. Pinder, E. Rakha, J. Bartlett, 2015, Histopathology.

PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression

E. Guccione, O. Barbash, A. Shaaban, 2017, Cell reports.

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

G. Ball, S. Lakhani, S. Pinder, 2018, European journal of cancer.

Addressing overtreatment of screen detected DCIS; the LORIS trial.

S. Pinder, M. Wallis, D. Rea, 2015, European journal of cancer.

Low grade Ductal Carcinoma in situ (DCIS): how best to describe it?

D. Rea, L. Fallowfield, A. Francis, 2014, Breast.

Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.

J. Donovan, S. Pinder, H. Earl, 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation

E. Provenzano, H. Earl, D. Rea, 2019, Journal of clinical epidemiology.

Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.

H. Earl, D. Rea, A. Makris, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right.

S. Pinder, D. Rea, E. Rakha, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Concordance between vacuum assisted biopsy and postoperative histology: implications for the proposed Low Risk DCIS Trial (LORIS).

A. Francis, N. Sharma, A. Hanby, 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Overtreatment of Low-Grade Ductal Carcinoma In Situ.

L. Fallowfield, A. Francis, 2016, JAMA oncology.

Breast screening saves lives: now is the time to address overtreatment.

D. Rea, A. Francis, 2014, Journal of comparative effectiveness research.

Time for a low-risk DCIS trial: harnessing public and patient involvement.

L. Fallowfield, A. Francis, M. Mackenzie, 2012, The Lancet. Oncology.

Time to stop operating on breast cancer patients with pathological complete response?

D. Rea, A. Francis, A. Tomlins, 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Multicentre prospective observational study evaluating recommendations for mastectomy by multidisciplinary teams

D. Rea, R. Bonomi, M. Wilcox, 2019, The British journal of surgery.

Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial

S. Pinder, M. Wallis, D. Rea, 2017, Annals of Surgical Oncology.

An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment

R. Peto, J. Donovan, T. Powles, 2018, Journal of clinical epidemiology.

Abstract P3-17-06: LORIS trial of active monitoring for DCIS: How does the online pathology eligibility review process work?

S. Pinder, A. Francis, A. Hanby, 2017 .

Opportunities and priorities for breast surgical research.

M. Reed, J. Harvey, J. Vaidya, 2018, The Lancet. Oncology.

OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.

S. Pinder, H. Earl, D. Rea, 2016 .